Department of Otolaryngology-Head and Neck Surgery, IRCCS Regina Elena National Cancer Institute, Rome, Italy; Department of Sense Organs, Sapienza University of Rome, Viale del Policlinico 155, 00186 Rome, Italy.
Division of Maxillofacial Surgery, Surgical Science Department, University of Torino, Torino, Italy.
Radiother Oncol. 2023 Jun;183:109547. doi: 10.1016/j.radonc.2023.109547. Epub 2023 Feb 20.
To answer an important question regarding the long-term morbidity of two oncological equivalent treatment for oropharyngeal squamous cell carcinoma (OPSCC), namely a comparison of swallowing function results between patients treated with trans-oral robotic surgery (TORS) versus patients treated with radiotherapy (RT).
Studies included patients with OPSCC treated with TORS or RT. Articles reporting complete data on MD Anderson Dysphagia Inventory (MDADI) and comparing the two treatments (TORS vs RT) were included in the meta-analysis. Swallowing assessed with MDADI was the primary outcome, the evaluation with instrumental methods was the secondary aim.
Included studies provided a total of 196 OPSCC primarily treated with TORS vs 283 OPSCC primarily treated with RT. The mean difference in MDADI score at the longest follow-up was not significantly different between TORS and RT group (mean difference [MD] -0.52; 95% CI -4.53-3.48; p = 0.80). After treatment, mean composite MDADI scores demonstrated a slight impairment in both groups without reaching a statistical difference compared to the baseline status. DIGEST score and Yale score showed a significantly worse function in both treatment groups at 12-month follow-up compared to baseline status.
The meta-analysis demonstrates that up-front TORS (+- adjuvant therapy) and up-front RT (+- CT) appear to be equivalent treatments in functional outcomes in T1-T2, N0-2 OPSCC, however, both treatments cause impaired swallowing ability. Clinicians should have a holistic approach and work with patients to develop an individualized nutrition plan and swallowing rehabilitation protocol from diagnosis to post-treatment surveillance.
为了回答关于口咽鳞状细胞癌(OPSCC)两种肿瘤等效治疗的长期发病率的一个重要问题,即比较经口机器人手术(TORS)与放疗(RT)治疗患者的吞咽功能结果。
纳入接受 TORS 或 RT 治疗的 OPSCC 患者的研究。纳入的研究均报告了 MD 安德森吞咽障碍量表(MDADI)的完整数据,并比较了两种治疗方法(TORS 与 RT)。使用 MDADI 评估吞咽功能是主要结局,使用仪器方法评估吞咽功能是次要目标。
纳入的研究共提供了 196 例主要接受 TORS 治疗的 OPSCC 和 283 例主要接受 RT 治疗的 OPSCC。最长随访时 MDADI 评分的平均差异在 TORS 组与 RT 组之间无显著差异(平均差异 [MD] -0.52;95%置信区间 [CI] -4.53-3.48;p=0.80)。治疗后,两组的平均综合 MDADI 评分均显示出轻微的损害,但与基线状态相比无统计学差异。12 个月随访时,DIGEST 评分和 Yale 评分均显示两组的功能较基线状态显著恶化。
荟萃分析表明,T1-T2、N0-2 期 OPSCC 患者的初始 TORS(+/-辅助治疗)和初始 RT(+/-CT)治疗在功能结局方面似乎是等效的治疗方法,但两种治疗方法均会导致吞咽能力受损。临床医生应采取整体方法,与患者合作,从诊断到治疗后监测,制定个体化的营养计划和吞咽康复方案。